24Research subjectResearch subjectChief: Associate Prof. Akira Shimizu））Outlook for students after graduationOutlook for students after graduationtion from non-pancreatic tissuesRAF/MEK/ERK pathway inhibition by sorafenibThe technologies of regenerative medicine lead to a novel treatment of organ dysfunction without organ or tissue transplantation after massive organ removal.The new methodology of cancer therapy improves outcomes in treatment of hepatobiliary pancreatic malignancies.Doctors can build careers as researchers in our lab or oversea study program, or as special-ists in hepatobiliary pancreatic surgery in University Hospital, or as board certified surgeons in gastroenterology in the affiliated hospitals.gastric cancerSince our research method uses a flow cytometer and a cell imaging device (Operetta), functional analysis of many genetic mutations and drug resistance can be efficiently evaluat-ed.Because you can learn a wide range of basic knowledge of cancer and research method us-ing the latest equipment, in the case of getting involved in cancer research and clinical work, the knowledge and technology obtained in this study seems very useful.Gene mutation increases the malignancy of cancer, but at the same time it may be-come a therapeutic targetUsing a flow cytometer (BD FACS Cant II), it is possible to obtain more objective and stable resultsThree-dimensional insulin-positive cellular aggregate resembled to pancreatic islet (in vitro)Insulin-positive cells in liver in situ induced by gene transfer technique(in vivo)RAS-mutated cellsGene mutated cancer cells are mea-sured with a flow cytometerSummary of ActivitySurgery has been the 1st choice in the treatment of hepatobiliary pancreatic ma-lignancies.We are aiming to clinical application and pursuing basic research, such as devel-opment of liver organoid and of pancreatic β cell by using regenerative medicine approaches, and establishment of new cancer targeting therapy.? Treatment of postpancreatectomy endocrine dysfunction using pancreatic β cell regenera-? Analysis of survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape ? Analysis of mechanisms of rapid liver regeneration in ALPPS model Outlook for researchSummary of ActivityThe basis of treatment for esophageal, gastric and colorectal cancer is surgical resection, and we are working on improving quality surgery further pursuing mini-mally invasive, radical and safety.We are also focusing on basic research directly linked to clinical practice. Using the flow cytometer and the latest cell imaging equipment Operetta, we aimed to develop new treatments targeting RAS and BRAF gene mutations of colorectal cancer and RhoA gene mutations of scirrhous gastric cancer.? Establishment of in vitro assay corresponding to individualized treatment of colorectal and ?Functional analysis of mutant RHOA in scirrhous gastric cancer?Intraoperative monitoring of recurrent nerve injury of esophageal surgeryOutlook for research（（Chief: Associate Prof. Akira ShimizuRegenerative medicine and treatment of malignancy - bench to bedside -From high quality surgery to gene therapy- New challenge to cancer treatment -Surgery (Gastroenterological)Hepatobiliary pancreatic surgeryHepatobiliary pancreatic surgerySurgery(Gastroenterological)Digestive tract surgeryDigestive tract surgery（（Chief: Assistant Prof. Yusuke MiyagawaChief: Assistant Prof. Yusuke Miyagawa））
元のページ ../index.html#26